Travere Therapeutics, Inc.
TVTX
$28.21
$0.411.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 110.46% | 114.22% | 87.94% | 75.65% | 60.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 110.46% | 114.22% | 87.94% | 75.65% | 60.55% |
| Cost of Revenue | -3.95% | -1.95% | -5.62% | -7.82% | -12.17% |
| Gross Profit | 3,357.84% | 1,102.10% | 303.17% | 153.34% | 107.14% |
| SG&A Expenses | 27.67% | 18.13% | 9.13% | 3.38% | -0.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.12% | 8.78% | 2.16% | -2.02% | -6.25% |
| Operating Income | 75.48% | 67.92% | 46.03% | 36.26% | 32.00% |
| Income Before Tax | 84.63% | 74.61% | 55.86% | 45.61% | 14.78% |
| Income Tax Expenses | 723.33% | -101.92% | -127.25% | -109.52% | -46.19% |
| Earnings from Continuing Operations | 84.32% | 74.63% | 55.93% | 45.66% | 14.80% |
| Earnings from Discontinued Operations | 2,801.09% | 100.16% | -100.02% | -100.32% | -100.35% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.06% | 74.81% | -15.86% | -40.70% | -188.64% |
| EBIT | 75.48% | 67.92% | 46.03% | 36.26% | 32.00% |
| EBITDA | 99.02% | 85.33% | 56.18% | 42.64% | 37.13% |
| EPS Basic | 92.89% | 77.02% | -8.73% | -33.93% | -156.92% |
| Normalized Basic EPS | 82.75% | 70.67% | 49.19% | 37.52% | 34.87% |
| EPS Diluted | 92.58% | 76.73% | -8.76% | -33.96% | -156.96% |
| Normalized Diluted EPS | 81.58% | 69.60% | 49.19% | 37.52% | 34.87% |
| Average Basic Shares Outstanding | 13.09% | 13.19% | 10.01% | 6.81% | 6.25% |
| Average Diluted Shares Outstanding | 17.33% | 17.53% | 10.01% | 6.81% | 6.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |